Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1996-1-17
|
pubmed:abstractText |
A significant minority of patients with COPD have favorable response to corticosteroid treatment. In addition, the benefit of corticosteroid treatment may be outweighed by the side effects. Long-term administration of inhaled steroids is a safe means of treatment. We hypothesized that treatment with high-dose inhaled budesonide would improve clinical symptoms and pulmonary function in subjects with COPD, and that the response to inhaled beta 2-agonist will serve to individualize steroid responders. We compared a 6-week course of 800 micrograms/d inhaled budesonide with placebo, separated by 4 weeks when no medication was taken, in a double-blind crossover trial, in 8 patients responding to inhaled beta 2-agonist, and in 22 nonresponders with stable COPD. In six of eight "responders to beta 2-agonist," there was a significant improvement in the FEV1 (defined as > or = 20%) following inhaled budesonide, as compared with placebo. In the 22 "nonresponders to beta 2-agonist," there was no significant improvement in the mean FEV1 (1.41 +/- 0.1 L before, and 1.61 +/- 0.1 L after treatment) with inhaled budesonide or placebo. Over the 6-week course of treatment by either budesonide or placebo, the nonresponders reported similar beta 2-agonist consumption (4.8 +/- 0.2 and 5.0 +/- 0.1 puffs per patient per day, respectively). However, there was a significant difference between the two periods of treatment in the responders as for the mean daily number of beta 2-agonist inhalations (2.4 +/- 0.1 in the budesonide period as compared with 5.3 +/- 0.1 in the placebo period; p < 0.005). We conclude that treatment with inhaled steroids improved spirometry data and inhaled beta 2-agonist consumption in about 25% of patients with stable COPD, and this rate is increased to about 75% in patients who respond to beta 2-agonist inhalation.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0012-3692
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
108
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1568-71
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7497762-Administration, Inhalation,
pubmed-meshheading:7497762-Adrenergic beta-Agonists,
pubmed-meshheading:7497762-Aged,
pubmed-meshheading:7497762-Bronchodilator Agents,
pubmed-meshheading:7497762-Budesonide,
pubmed-meshheading:7497762-Cross-Over Studies,
pubmed-meshheading:7497762-Double-Blind Method,
pubmed-meshheading:7497762-Female,
pubmed-meshheading:7497762-Forced Expiratory Volume,
pubmed-meshheading:7497762-Humans,
pubmed-meshheading:7497762-Lung Diseases, Obstructive,
pubmed-meshheading:7497762-Male,
pubmed-meshheading:7497762-Middle Aged,
pubmed-meshheading:7497762-Pregnenediones,
pubmed-meshheading:7497762-Spirometry
|
pubmed:year |
1995
|
pubmed:articleTitle |
Inhaled budesonide therapy for patients with stable COPD.
|
pubmed:affiliation |
Department of Medicine A, Hillel-Yaffe Medical Center, Hadera, Israel.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|